Skip to content

A study to see if cancer is hereditary based on gene sequencing in cases except breast and ovarian cancers

GENE-North: Germline Next-Generation Sequencing to Uncover Pathogenic and Familial Cancer Genes in Solid Cancers (other than Breast and Ovary) in North India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/104473
Enrollment
1400
Registered
2026-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C01- Malignant neoplasm of base of tongue Health Condition 2: C006- Malignant neoplasm of commissure of lip, unspecified Health Condition 3: C020- Malignant neoplasm of dorsal surface of tongue Health Condition 4: C002- Malignant neoplasm of external lip, unspecified Health Condition 5: C001- Malignant neoplasm of external lower lip Health Condition 6: C000- Malignant neoplasm of external upper lip Health Condition 7: C009- Malignant neoplasm of lip, unspecified Health Condit

Interventions

Intervention1: Nil: Nil

Sponsors

TRAC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults greater than or equal to 18 years with histologically confirmed solid cancers (non breast and ovary) (all subtypes and all stages) like renal cell carcinoma (RCC), colorectal, endometrial, pancreatic, prostate, thyroid, lung head-neck, rare tumors

Exclusion criteria

Exclusion criteria: Inability to consent or inadequate DNA

Design outcomes

Primary

MeasureTime frame
Pathogenic or likely pathogenic prevalenceTimepoint: After analysis of the sequencing result

Secondary

MeasureTime frame
Proportion of variants in syndrome-associated versus non-syndromic cancer genesTimepoint: After analysis of the sequencing result and getting the clinical information;Association of predictors of Pathogenic or likely pathogenic (age less than 45, bilateral/ or multifocal disease, histology, family history)Timepoint: After analysis of the sequencing result and getting the clinical information;Proportion of variants with potential therapeutic or preventive implicationsTimepoint: After analysis of the sequencing result and getting the clinical information

Countries

India

Contacts

Public ContactMOITRI BASU

Homi Bhabha Cancer Hospital and Research Centre

moitrri_basu@yahoo.co.in09831272614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026